Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced a new member of its board of directors. Avram Miller, cofounder of Intel Capital, will join the board and will also serve in an advisory role, bringing his invaluable experience to contribute to the company’s strategy and business development efforts. Miller’s impressive decades-long career includes strategic and responsible roles in both the technology and medical industries. After spending 13 years in the medical science space, he moved to high tech where, in addition to cofounding Intel Capital, he served as the company’s corporate vice president of business development. In the last decade, he has found a way to combine technology with health care, including serving in an advisory role to prominent institutions such as the Cleveland Clinic and Sheba Medical Center and coaching as well as investing in many early-stage med-tech startups.
“Avram’s unique background in medical science and technology and, in particular, his experience dealing with the opportunities fueled by rapid technological changes will help guide our business,” said Renovaro Biosciences board chair Rene Sindlev in the press release. “We believe his vast business experience working with companies at all stages of development will be instrumental as we move into the commercial phase of our business.”
To view the full press release, visit https://ibn.fm/HkB3Q
About Renovaro BioSciences Inc.
Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN